Abstract

Background

The International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-level from expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns.

Methods

Two surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians.

Results

438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by > 85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by > 72% of laboratories.

Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with geographical and expertise-related differences.

Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative.

Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest.

Conclusion

This survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.

Details

Title
Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey
Author
Lieve, Van Hoovels 1   VIAFID ORCID Logo  ; Broeders Sylvia 2 ; Chan Edward K L 3 ; Andrade, Luis 4 ; de Melo Cruvinel Wilson 5 ; Damoiseaux Jan 6 ; Viander Markku 7 ; Herold Manfred 8 ; Coucke Wim 2 ; Heijnen Ingmar 9 ; Bogdanos Dimitrios 10 ; Calvo-Alén, Jaime 11 ; Eriksson Catharina 12 ; Kozmar Ana 13 ; Kuhi Liisa 14 ; Bonroy Carolien 15 ; Lauwerys Bernard 16 ; Schouwers Sofie 17 ; Lutteri Laurence 18 ; Vercammen Martine 19 ; Mayer, Miroslav 20 ; Patel, Dina 21 ; Egner, William 21 ; Puolakka Kari 22 ; Tesija-Kuna Andrea 13 ; Shoenfeld Yehuda 23 ; de Sousa Maria José Rego 24 ; Hoyos Marcos Lopez 25 ; Radice Antonella 26 ; Bossuyt Xavier 27 

 OLV Hospital, Department of Laboratory Medicine, Aalst, Belgium (GRID:grid.416672.0) (ISNI:0000 0004 0644 9757); KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Sciensano (Formerly Scientific Institute of Public Health), Brussels, Belgium (GRID:grid.508031.f) 
 University of Florida, Department of Oral Biology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091) 
 Universidade Federal de São Paulo, Escola Paulista de Medicina, Rheumatology Division, Sao Paulo, Brazil (GRID:grid.411249.b) (ISNI:0000 0001 0514 7202) 
 Pontifícia Universidade católica de Goiás, Goiânia, Brazil (GRID:grid.412263.0) (ISNI:0000 0001 2355 1516) 
 MUMC, Centraal Diagnostisch Laboratorium, Maastricht, The Netherlands (GRID:grid.412966.e) (ISNI:0000 0004 0480 1382) 
 University of Turku, Department of Medical Microbiology and Immunology, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371) 
 Medical University of Innsbruck, Rheumatology Laboratory, Department of Internal Medicine II, Innsbruck, Austria (GRID:grid.5361.1) (ISNI:0000 0000 8853 2677) 
 University Hospital Basel, Medical Immunology, Laboratory Medicine, Basel, Switzerland (GRID:grid.410567.1) 
10  University of Thessaly, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, Larissa, Greece (GRID:grid.410558.d) (ISNI:0000 0001 0035 6670) 
11  Hospital Universitario Araba, Servicio de Reumatología, Vitoria, Spain (GRID:grid.468902.1) (ISNI:0000 0004 1773 0974) 
12  Umeå University, Department of Clinical Microbiology, Umeå, Sweden (GRID:grid.12650.30) (ISNI:0000 0001 1034 3451) 
13  University Hospital Centre Zagreb, Department of Laboratory Diagnostics, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648) 
14  East Tallin Central Hospital, Central Laboratory, Tallin, Estonia (GRID:grid.412688.1) 
15  Ghent University, Department of Internal Medicine, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); Ghent University, Department of Diagnostic Sciences, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798) 
16  Université Catholique de Louvain, Pôle de Pathologies Rhumatismales Et systémiques, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); Cliniques Universitaires Saint-Luc, Department of Rheumatology, Brussels, Belgium (GRID:grid.48769.34) (ISNI:0000 0004 0461 6320) 
17  GZA Hospitals, Department of Laboratory Medicine, Antwerp, Belgium (GRID:grid.428965.4) (ISNI:0000 0004 7536 2436) 
18  University Hospital Liège, Department of Clinical Chemistry, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858) 
19  AZ Sint-Jan Hospital Bruges-Ostend, Department of Laboratory Medicine, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792); Vrije Universiteit Brussel, Research Group Reproductive Immunology and Implantation (REIM), Brussels, Belgium (GRID:grid.8767.e) (ISNI:0000 0001 2290 8069) 
20  University Hospital Centre Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648) 
21  UK NEQAS Immunology, Northern General Hospital, Sheffield, UK (GRID:grid.412937.a) (ISNI:0000 0004 0641 5987) 
22  South Karelia Central Hospital, Department of Medicine, Lappeenranta, Finland (GRID:grid.416155.2) (ISNI:0000 0004 0628 2117) 
23  Saint Petersburg State University, Laboratory of the Mosaic of Autoimmunity, Saint-Petersburg, Russian Federation (GRID:grid.15447.33) (ISNI:0000 0001 2289 6897); Sheba Medical Center, Affiliated to Tel-Aviv University School of Medicine, Tel-Hashomer, Zabludowicz Center for Autoimmune Diseases, Tel Aviv, Israel (GRID:grid.413795.d) (ISNI:0000 0001 2107 2845) 
24  Laboratorial Germano de Sousa, Centro de Medicina, Lisboa, Portugal (GRID:grid.413795.d) 
25  Hospital Universitario Marqués de Valdecilla, Servicio de Inmunología, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262) 
26  UOC Microbiologia e Virologia, Presidio Ospedaliero San Carlo Borromeo, Milan, Italy (GRID:grid.411325.0) 
27  KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); University Hospital Leuven, Department of Laboratory Medicine, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
Publication year
2020
Publication date
Dec 2020
Publisher
Springer Nature B.V.
ISSN
2038-0305
e-ISSN
2038-3274
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2473384708
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.